Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603305093> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2603305093 endingPage "8600" @default.
- W2603305093 startingPage "8600" @default.
- W2603305093 abstract "8600 Background: The combination of bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (VDTPACE) was developed as an intense regimen for disease control prior to tandem transplantation for multiple myeloma (MM) in total therapy protocols. The regimen is very effective in this setting, and since has also been used in the relapsed setting. We examined the outcomes of a set of patients undergoing VDTPACE therapy for relapsed MM at our institution. Methods: We identified 71 patients who received VDTPACE for relapsed MM, at Mayo Clinic from 7/2006 to 7/2012. Plasma cell leukemia was excluded. All data was extracted from clinical records. Results: The median age of patients was 59 years (range, 39-80); 48 (67.6%) were male. The median time from diagnosis to initiation of VDTPACE was 38.2 months (range, 2-125). The median number of cycles given was 1 (range, 1-9). The overall response rate after one cycle was 57.1% (14.3% VGPR, 22.2% PR and 20.6% MR) in the 63 patients in whom the response was evaluable. The median overall survival (OS) post-VDTPACE was 8.2 months (95% CI, 5.7-10.9). Eighteen (25.4%) patients went on to autologous stem cell transplantation (SCT), and 7 (9.9%) received matched allogeneic SCT following VDTPACE, and the median OS post-VDTPACE was significantly longer for these groups compared to those who were not transplanted (15.3 and 20.5 months, respectively vs 5 months, p-value <0.001). Thirty eight of 66 (57.6%) patients were rehospitalized after initial admission for infusion therapy for a median duration of 6 days (range, 1-26). The median platelet and red cell transfusions were 4 (range, 0-21) and 5 (range, 0-22) units, respectively. Renal toxicity was seen in 13/62 (21%) patients and 27/65 (41.5%) patients developed neutropenic fever. The median duration to absolute neutrophil and platelet count recovery was 18 (range 12-42) and 27 (range, 12-42) days, respectively. Three (4.2%) patients died within 30 days and 11 (15.5%) within 8 weeks of initiating VDTPACE. Conclusions: VDTPACE is an effective therapy in relapsed MM but is associated with significant morbidity and short-term mortality. It appears to be more effective when followed by an autologous or allogeneic SCT." @default.
- W2603305093 created "2017-04-07" @default.
- W2603305093 creator A5001453763 @default.
- W2603305093 creator A5002248011 @default.
- W2603305093 creator A5007507517 @default.
- W2603305093 creator A5007747233 @default.
- W2603305093 creator A5012403700 @default.
- W2603305093 creator A5026574827 @default.
- W2603305093 creator A5033220547 @default.
- W2603305093 creator A5036150860 @default.
- W2603305093 creator A5051470930 @default.
- W2603305093 creator A5052346975 @default.
- W2603305093 creator A5054957898 @default.
- W2603305093 creator A5064593008 @default.
- W2603305093 creator A5068637846 @default.
- W2603305093 creator A5072347487 @default.
- W2603305093 creator A5072502164 @default.
- W2603305093 creator A5076611748 @default.
- W2603305093 date "2013-05-20" @default.
- W2603305093 modified "2023-09-26" @default.
- W2603305093 title "Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma." @default.
- W2603305093 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.8600" @default.
- W2603305093 hasPublicationYear "2013" @default.
- W2603305093 type Work @default.
- W2603305093 sameAs 2603305093 @default.
- W2603305093 citedByCount "1" @default.
- W2603305093 countsByYear W26033050932018 @default.
- W2603305093 crossrefType "journal-article" @default.
- W2603305093 hasAuthorship W2603305093A5001453763 @default.
- W2603305093 hasAuthorship W2603305093A5002248011 @default.
- W2603305093 hasAuthorship W2603305093A5007507517 @default.
- W2603305093 hasAuthorship W2603305093A5007747233 @default.
- W2603305093 hasAuthorship W2603305093A5012403700 @default.
- W2603305093 hasAuthorship W2603305093A5026574827 @default.
- W2603305093 hasAuthorship W2603305093A5033220547 @default.
- W2603305093 hasAuthorship W2603305093A5036150860 @default.
- W2603305093 hasAuthorship W2603305093A5051470930 @default.
- W2603305093 hasAuthorship W2603305093A5052346975 @default.
- W2603305093 hasAuthorship W2603305093A5054957898 @default.
- W2603305093 hasAuthorship W2603305093A5064593008 @default.
- W2603305093 hasAuthorship W2603305093A5068637846 @default.
- W2603305093 hasAuthorship W2603305093A5072347487 @default.
- W2603305093 hasAuthorship W2603305093A5072502164 @default.
- W2603305093 hasAuthorship W2603305093A5076611748 @default.
- W2603305093 hasConcept C126322002 @default.
- W2603305093 hasConcept C141071460 @default.
- W2603305093 hasConcept C2776364478 @default.
- W2603305093 hasConcept C2776694085 @default.
- W2603305093 hasConcept C2777408962 @default.
- W2603305093 hasConcept C2777478702 @default.
- W2603305093 hasConcept C2778119113 @default.
- W2603305093 hasConcept C2778684742 @default.
- W2603305093 hasConcept C2779050716 @default.
- W2603305093 hasConcept C2779609412 @default.
- W2603305093 hasConcept C2779709957 @default.
- W2603305093 hasConcept C2780353925 @default.
- W2603305093 hasConcept C2781413609 @default.
- W2603305093 hasConcept C2911091166 @default.
- W2603305093 hasConcept C71924100 @default.
- W2603305093 hasConcept C90924648 @default.
- W2603305093 hasConceptScore W2603305093C126322002 @default.
- W2603305093 hasConceptScore W2603305093C141071460 @default.
- W2603305093 hasConceptScore W2603305093C2776364478 @default.
- W2603305093 hasConceptScore W2603305093C2776694085 @default.
- W2603305093 hasConceptScore W2603305093C2777408962 @default.
- W2603305093 hasConceptScore W2603305093C2777478702 @default.
- W2603305093 hasConceptScore W2603305093C2778119113 @default.
- W2603305093 hasConceptScore W2603305093C2778684742 @default.
- W2603305093 hasConceptScore W2603305093C2779050716 @default.
- W2603305093 hasConceptScore W2603305093C2779609412 @default.
- W2603305093 hasConceptScore W2603305093C2779709957 @default.
- W2603305093 hasConceptScore W2603305093C2780353925 @default.
- W2603305093 hasConceptScore W2603305093C2781413609 @default.
- W2603305093 hasConceptScore W2603305093C2911091166 @default.
- W2603305093 hasConceptScore W2603305093C71924100 @default.
- W2603305093 hasConceptScore W2603305093C90924648 @default.
- W2603305093 hasIssue "15_suppl" @default.
- W2603305093 hasLocation W26033050931 @default.
- W2603305093 hasOpenAccess W2603305093 @default.
- W2603305093 hasPrimaryLocation W26033050931 @default.
- W2603305093 hasRelatedWork W2000847356 @default.
- W2603305093 hasRelatedWork W2058195404 @default.
- W2603305093 hasRelatedWork W2110863304 @default.
- W2603305093 hasRelatedWork W2166088247 @default.
- W2603305093 hasRelatedWork W2353124159 @default.
- W2603305093 hasRelatedWork W2414712747 @default.
- W2603305093 hasRelatedWork W2559593973 @default.
- W2603305093 hasRelatedWork W3024147820 @default.
- W2603305093 hasRelatedWork W3028774359 @default.
- W2603305093 hasRelatedWork W4239955546 @default.
- W2603305093 hasVolume "31" @default.
- W2603305093 isParatext "false" @default.
- W2603305093 isRetracted "false" @default.
- W2603305093 magId "2603305093" @default.
- W2603305093 workType "article" @default.